Intuitive Surgical (ISRG) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Intuitive Surgical (NASDAQ: ISRG):

• 10/22/2026 – Intuitive Surgical was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/21/2026 – Intuitive Surgical was given a new $503.00 price target by Leerink Partners. They now have an “outperform” rating on the stock.
• 10/21/2026 – Intuitive Surgical had its “outperform” rating reaffirmed by Oppenheimer. They now have a $500.00 price target on the stock.
• 10/21/2026 – Intuitive Surgical had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $486.00 price target on the stock, down from $487.00.
• 10/21/2026 – Intuitive Surgical had its “overweight” rating reaffirmed by Barclays. They now have a $500.00 price target on the stock, up from $485.00.
• 10/21/2026 – Intuitive Surgical had its “outperform” rating reaffirmed by Raymond James Financial. They now have a $480.00 price target on the stock.
• 10/21/2026 – Intuitive Surgical had its price target raised by JPMorgan Chase & Co. from $450.00 to $475.00. They now have an “overweight” rating on the stock.
• 10/21/2026 – Intuitive Surgical had its price target lowered by Royal Bank Of Canada from $575.00 to $550.00. They now have an “outperform” rating on the stock.
• 10/21/2026 – Intuitive Surgical had its price target lowered by Mizuho from $415.00 to $400.00. They now have a “neutral” rating on the stock.
• 10/21/2026 – Intuitive Surgical had its “buy” rating reaffirmed by BTIG Research. They now have a $454.00 price target on the stock.
• 10/21/2026 – Intuitive Surgical had its price target raised by Robert W. Baird from $513.00 to $550.00. They now have an “outperform” rating on the stock.
• 10/21/2026 – Intuitive Surgical was upgraded by Erste Group Bank from “hold” to “buy”.
• 10/19/2026 – Intuitive Surgical had its “buy” rating reaffirmed by TD Cowen. They now have a $485.00 price target on the stock.
• 10/13/2026 – Intuitive Surgical had its “buy” rating reaffirmed by UBS Group.
• 10/13/2026 – Intuitive Surgical was given a new $415.00 price target by Mizuho.
• 10/12/2026 – Intuitive Surgical had its price target lowered by BTIG Research from $469.00 to $454.00. They now have a “buy” rating on the stock.
• 10/7/2026 – Intuitive Surgical was upgraded by Barclays to “strong-buy”.
• 10/6/2026 – Intuitive Surgical is now covered by Barclays. They set an “overweight” rating and a $485.00 price target on the stock.
• 9/20/2026 – Intuitive Surgical was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/12/2026 – Intuitive Surgical was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/8/2026 – Intuitive Surgical had its “buy” rating reaffirmed by BTIG Research. They now have a $469.00 price target on the stock.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Mark Brosius sold 61 shares of the firm’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $441.60, for a total transaction of $26,937.60. Following the completion of the transaction, the executive vice president directly owned 581 shares in the company, valued at $256,569.60. This trade represents a 9.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia L. Wadors sold 1,078 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $443.80, for a total transaction of $478,416.40. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 38,806 shares of company stock valued at $16,824,795 over the last three months. 0.60% of the stock is currently owned by corporate insiders.

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.